Cedarbaum JM - Search Results

1

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A. Guttman M, et al. Among authors: cedarbaum jm. Mov Disord. 1993 Jul;8(3):298-304. doi: 10.1002/mds.870080308. Mov Disord. 1993. PMID: 8341294

2

3-O-methyldopa administration does not alter fluorodopa transport into the brain.

Guttman M, Léger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. Guttman M, et al. Among authors: cedarbaum jm. Ann Neurol. 1992 Jun;31(6):638-43. doi: 10.1002/ana.410310611. Ann Neurol. 1992. PMID: 1514775

3

Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.

Cedarbaum JM, Léger G, Reches A, Guttman M. Cedarbaum JM, et al. Clin Neuropharmacol. 1990 Dec;13(6):544-52. doi: 10.1097/00002826-199012000-00006. Clin Neuropharmacol. 1990. PMID: 2276119

4

Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.

Cedarbaum JM, Leger G, Guttman M. Cedarbaum JM, et al. Clin Neuropharmacol. 1991 Aug;14(4):330-42. doi: 10.1097/00002826-199108000-00005. Clin Neuropharmacol. 1991. PMID: 1913700

5

The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA. Eidelberg D, et al. Mov Disord. 1990;5(3):203-13. doi: 10.1002/mds.870050304. Mov Disord. 1990. PMID: 2117706

6

Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.

Gaurav R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, Biondetti E, Valabrègue R, Ewenczyk C, Hutchison RM, Cedarbaum JM, Corvol JC, Vidailhet M, Lehéricy S. Gaurav R, et al. Among authors: cedarbaum jm. Mov Disord. 2021 Jul;36(7):1592-1602. doi: 10.1002/mds.28531. Epub 2021 Mar 10. Mov Disord. 2021. PMID: 33751655 Free PMC article.

7

Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.

Cedarbaum JM, Clark M, Toy LH, Green-Parsons A. Cedarbaum JM, et al. Mov Disord. 1990;5(4):298-303. doi: 10.1002/mds.870050407. Mov Disord. 1990. PMID: 1979657

8

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee. Vizcarra JA, et al. Among authors: cedarbaum jm. Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. Mov Disord. 2019. PMID: 30901492 Free PMC article. No abstract available.

9

Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.

Mirelman A, Hillel I, Rochester L, Del Din S, Bloem BR, Avanzino L, Nieuwboer A, Maidan I, Herman T, Thaler A, Gurevich T, Kestenbaum M, Orr-Urtreger A, Brys M, Cedarbaum JM, Giladi N, Hausdorff JM. Mirelman A, et al. Among authors: cedarbaum jm. Mov Disord. 2020 Jun;35(6):959-968. doi: 10.1002/mds.28006. Epub 2020 Feb 20. Mov Disord. 2020. PMID: 32080891

10

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.

Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D. Mollenhauer B, et al. Among authors: cedarbaum jm. Mov Disord. 2020 Nov;35(11):1999-2008. doi: 10.1002/mds.28206. Epub 2020 Aug 15. Mov Disord. 2020. PMID: 32798333 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters